Literature DB >> 8143888

Accumulation of new quinolones in the blood of elderly patients.

M Morita1, A Hasuda, H Nakagawa, Y Abe, K Suzuki.   

Abstract

The correlation between serum levels of five new quinolones (norfloxacin, ofloxacin, enoxacin, ciprofloxacin and lomefloxacin), age and 24 h creatinine clearance was studied in 180 patients. One of five new quinolones was orally administered, before transurethral resection of the prostate, at the dosage of 200 mg three times daily for 3 consecutive days. Serum levels were checked 5.5 h or about 17 h after the final administration. Creatinine clearance was found to be negatively correlated with aging (P < 0.001). After oral administration, the level of certain accumulated new quinolones in serum increased with the age of patients (P < 0.001-0.1). This tendency was more marked for ofloxacin, lomefloxacin and enoxacin than for ciprofloxacin and norfloxacin. The investigators concluded that the level of accumulated new quinolones in serum with aging is correlated to the 24 h urinary excretion rate of each new quinolone. These results indicate that ofloxacin, lomefloxacin and enoxacin, which have higher 24 h urinary excretion rates, should be administered at lower doses according to the age of the patient, in order to prevent adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8143888     DOI: 10.1177/030006059302100604

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

Review 1.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 2.  Quinolones in the aged.

Authors:  L E Nicolle
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Photosensitivity reactions caused by lomefloxacin hydrochloride: a multicenter survey.

Authors:  J Arata; T Horio; R Soejima; K Ohara
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.